Guardion Health Sciences (GHSI) Stock Forecast, Price Target & Predictions
GHSI Stock Forecast
Guardion Health Sciences stock forecast is as follows: an average price target of $0.01 (represents a -99.88% downside from GHSI’s last price of $10.19) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
GHSI Price Target
The average price target for Guardion Health Sciences (GHSI) is $0.01 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $0.01 to $0.01. This represents a potential -99.88% downside from GHSI's last price of $10.19.
GHSI Analyst Ratings
According to 1 Wall Street analysts, Guardion Health Sciences's rating consensus is 'Buy'. The analyst rating breakdown for GHSI stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Guardion Health Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 09, 2022 | Anthony Vendetti | Hovde Group | $0.01 | - | 156.19% | -99.88% |
The latest Guardion Health Sciences stock forecast, released on Mar 09, 2022 by Anthony Vendetti from Hovde Group, set a price target of $0.01, which represents a 156.19% increase from the stock price at the time of the forecast (-), and a -99.88% decrease from GHSI last price ($10.19).
Guardion Health Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $10.19 | $10.19 | $10.19 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Guardion Health Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Guardion Health Sciences's last price of $10.19. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Mar 09, 2022 | Maxim Group | - | Buy | Initialise |
Guardion Health Sciences's last stock rating was published by Maxim Group on Mar 09, 2022. The company Initialise its GHSI rating from "null" to "Buy".
Guardion Health Sciences Financial Forecast
Guardion Health Sciences Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $3.34M | $2.79M | $3.19M | $2.73M | $2.66M | $3.28M | $2.38M | $2.63M |
| Avg Forecast | $3.62M | $3.50M | $3.21M | $3.12M | $2.96M | $3.08M | $2.78M | $2.59M | $2.70M | $3.55M | $2.60M | $2.21M | $2.59M |
| High Forecast | $3.62M | $3.50M | $3.21M | $3.12M | $2.96M | $3.08M | $2.78M | $2.59M | $2.70M | $3.55M | $2.60M | $2.21M | $2.59M |
| Low Forecast | $3.62M | $3.50M | $3.21M | $3.12M | $2.96M | $3.08M | $2.78M | $2.59M | $2.70M | $3.55M | $2.60M | $2.21M | $2.59M |
| # Analysts | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | 1.08% | 1.00% | 1.23% | 1.01% | 0.75% | 1.26% | 1.08% | 1.01% |
Guardion Health Sciences's average Quarter revenue forecast for Dec 23 based on 1 analysts is $2.96M, with a low forecast of $2.96M, and a high forecast of $2.96M. GHSI's average Quarter revenue forecast represents a -11.21% decrease compared to the company's last Quarter revenue of $3.34M (Sep 23).
Guardion Health Sciences EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | $-1.82M | $-752.52K | $-3.36M | $6.74M | $-1.41M | $-1.39M | $-2.25M | $-14.31M |
| Avg Forecast | $-2.29M | $-2.22M | $-2.03M | $-1.98M | $-1.88M | $-1.95M | $-1.76M | $-1.64M | $-1.71M | $-2.25M | $-1.65M | $-2.59M | $-1.64M |
| High Forecast | $-2.29M | $-2.22M | $-2.03M | $-1.98M | $-1.88M | $-1.95M | $-1.76M | $-1.64M | $-1.71M | $-2.25M | $-1.65M | $-2.07M | $-1.64M |
| Low Forecast | $-2.29M | $-2.22M | $-2.03M | $-1.98M | $-1.88M | $-1.95M | $-1.76M | $-1.64M | $-1.71M | $-2.25M | $-1.65M | $-3.10M | $-1.64M |
| Surprise % | - | - | - | - | - | 0.93% | 0.43% | 2.04% | -3.94% | 0.63% | 0.85% | 0.87% | 8.71% |
0 analysts predict GHSI's average Quarter EBITDA for Mar 23 to be $-1.64M, with a high of $-1.64M and a low of $-1.64M. This is -124.39% lower than Guardion Health Sciences's previous annual EBITDA (Dec 22) of $6.74M.
Guardion Health Sciences Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | $372.63K | $-1.17M | $2.53M | $-24.25M | $-1.66M | $-1.69M | $-2.64M | $-14.52M |
| Avg Forecast | $-359.56K | $-744.81K | $-847.54K | $-1.13M | $-937.43K | $-1.04M | $-1.19M | $-1.45M | $-1.93M | $-1.61M | $-2.89M | $-2.95M | $-50.72M |
| High Forecast | $-359.56K | $-744.81K | $-847.54K | $-1.13M | $-937.43K | $-1.04M | $-1.19M | $-1.45M | $-1.93M | $-1.61M | $-2.89M | $-2.36M | $-50.72M |
| Low Forecast | $-359.56K | $-744.81K | $-847.54K | $-1.13M | $-937.43K | $-1.04M | $-1.19M | $-1.45M | $-1.93M | $-1.61M | $-2.89M | $-3.53M | $-50.72M |
| Surprise % | - | - | - | - | - | -0.36% | 0.98% | -1.74% | 12.59% | 1.04% | 0.59% | 0.90% | 0.29% |
Guardion Health Sciences's average Quarter net income forecast for Dec 23 is $-937.43K, with a range of $-937.43K to $-937.43K. GHSI's average Quarter net income forecast represents a -351.57% decrease compared to the company's last Quarter net income of $372.63K (Sep 23).
Guardion Health Sciences SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | $2.22M | $2.18M | $2.74M | $2.19M | $2.76M | $3.02M | $3.69M | $3.73M |
| Avg Forecast | $13.28M | $12.86M | $11.78M | $11.46M | $10.88M | $11.29M | $10.22M | $9.52M | $9.91M | $13.04M | $9.55M | $8.11M | $9.52M |
| High Forecast | $13.28M | $12.86M | $11.78M | $11.46M | $10.88M | $11.29M | $10.22M | $9.52M | $9.91M | $13.04M | $9.55M | $8.11M | $9.52M |
| Low Forecast | $13.28M | $12.86M | $11.78M | $11.46M | $10.88M | $11.29M | $10.22M | $9.52M | $9.91M | $13.04M | $9.55M | $8.11M | $9.52M |
| Surprise % | - | - | - | - | - | 0.20% | 0.21% | 0.29% | 0.22% | 0.21% | 0.32% | 0.45% | 0.39% |
Guardion Health Sciences's average Quarter SG&A projection for Dec 23 is $10.88M, based on 1 Wall Street analysts, with a range of $10.88M to $10.88M. The forecast indicates a 389.47% rise compared to GHSI last annual SG&A of $2.22M (Sep 23).
Guardion Health Sciences EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | $0.29 | $-0.93 | $2.00 | $-19.85 | $-1.35 | $-1.37 | $-3.37 | $-0.01 |
| Avg Forecast | $-0.28 | $-0.58 | $-0.66 | $-0.88 | $-0.73 | $-0.81 | $-0.93 | $-1.13 | $-1.50 | $-1.25 | $-2.25 | $-4.00 | $-39.50 |
| High Forecast | $-0.28 | $-0.58 | $-0.66 | $-0.88 | $-0.73 | $-0.81 | $-0.93 | $-1.13 | $-1.50 | $-1.25 | $-2.25 | $-4.00 | $-39.50 |
| Low Forecast | $-0.28 | $-0.58 | $-0.66 | $-0.88 | $-0.73 | $-0.81 | $-0.93 | $-1.13 | $-1.50 | $-1.25 | $-2.25 | $-4.00 | $-39.50 |
| Surprise % | - | - | - | - | - | -0.36% | 1.00% | -1.77% | 13.23% | 1.08% | 0.61% | 0.84% | 0.00% |
According to 1 Wall Street analysts, Guardion Health Sciences's projected average Quarter EPS for Dec 23 is $-0.73, with a low estimate of $-0.73 and a high estimate of $-0.73. This represents a -351.72% decrease compared to GHSI previous annual EPS of $0.29 (Sep 23).
Guardion Health Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AQST | Aquestive Therapeutics | $4.79 | $9.50 | 98.33% | Buy |
| ORGO | Organogenesis | $2.91 | $5.00 | 71.82% | Buy |
| LFCR | Lifecore Biomedical | $5.08 | $8.00 | 57.48% | Buy |
| CYTH | Cyclo Therapeutics | $0.65 | $0.95 | 46.15% | Buy |
| AGRX | Agile Therapeutics | $1.51 | $1.00 | -33.77% | Buy |
| GHSI | Guardion Health Sciences | $10.19 | $0.01 | -99.90% | Buy |
GHSI Forecast FAQ
Is Guardion Health Sciences a good buy?
Yes, according to 1 Wall Street analysts, Guardion Health Sciences (GHSI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of GHSI's total ratings.
What is GHSI's price target?
Guardion Health Sciences (GHSI) average price target is $0.012 with a range of $0.012 to $0.012, implying a -99.88% from its last price of $10.19. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Guardion Health Sciences stock go up soon?
According to Wall Street analysts' prediction for GHSI stock, the company can go down by -99.88% (from the last price of $10.19 to the average price target of $0.012), down by -99.88% based on the highest stock price target, and down by -99.88% based on the lowest stock price target.
Can Guardion Health Sciences stock reach $20?
GHSI's average twelve months analyst stock price target of $0.012 does not support the claim that Guardion Health Sciences can reach $20 in the near future.
What are Guardion Health Sciences's analysts' financial forecasts?
GHSI's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $13.45M (high $13.45M, low $13.45M), average EBITDA is $-8.522M (high $-8.522M, low $-8.522M), average net income is $-3.082M (high $-3.082M, low $-3.082M), average SG&A $49.38M (high $49.38M, low $49.38M), and average EPS is $-2.4 (high $-2.4, low $-2.4).
Did the GHSI's actual financial results beat the analysts' financial forecasts?
Based on Guardion Health Sciences's last annual report (Dec 2023), the company's revenue was $12.25M, beating the average analysts forecast of $11.42M by 7.28%. Apple's EBITDA was $-4.336M, missing the average prediction of $-7.234M by -40.06%. The company's net income was $158.03K, missing the average estimation of $-4.623M by -103.42%. Apple's SG&A was $9.58M, missing the average forecast of $41.92M by -77.14%. Lastly, the company's EPS was $0, missing the average prediction of $-3.6 by -100.00%. In terms of the last quarterly report (Sep 2023), Guardion Health Sciences's revenue was $3.34M, beating the average analysts' forecast of $3.08M by 8.49%. The company's EBITDA was $-1.819M, missing the average prediction of $-1.949M by -6.68%. Guardion Health Sciences's net income was $372.63K, missing the average estimation of $-1.04M by -135.82%. The company's SG&A was $2.22M, missing the average forecast of $11.29M by -80.32%. Lastly, the company's EPS was $0.29, missing the average prediction of $-0.81 by -135.80%